Shitanshu Uppal
Publications Update # 79
Strategies to overcome workaholism, prevent surgical site infections, and conduct the STOP-IT trial and BALANCE trial to reduce antibiotic duration.
PAOLA-1: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer (Overall Survival)
Olaparib combined with bevacizumab provided a OS benefit for HRD-positive ovarian cancer patients.
GYOEDU Resident: BRCA, Genetics and Parp Inhibitors
PARP Trials List
Open source article to read for reference
Leadership Styles
As a new attending or a fellow supervising a team
GYOEDU Resident: Ovarian Cancer - PART 1
GYOEDU Subscription FAQs
GYOEDU offers a tiered subscription system where each additional service
The Living Room
Originally featured in Publications Update # 77
Warning: This podcast episode
Keynote B21 - Pembrolizumab in High-Risk Endometrial Cancer (Video Explainer)
Video Explaining B-21 Trial
Keynote B-21: Pembrolizumab vs. Placebo in High-risk Endometrial Cancer
Adjuvant Pembrolizumab did not improve DFS in high-risk endometrial cancer population